 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...5657585960616263646566...7475» |
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Enrollment change: CARE-ROP: Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity (clinicaltrials.gov) - Oct 5, 2016
P2, N=19, Active, not recruiting, Sponsor: University Hospital Freiburg
Recruiting --> Active, not recruiting | N=40 --> 19
- Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: SwapTwo: Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab (clinicaltrials.gov) - Sep 30, 2016
P4, N=20, Recruiting, Sponsor: Rishi Singh
Recruiting --> Active, not recruiting | N=40 --> 19 Trial primary completion date: Nov 2016 --> Nov 2018
- || Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO) (clinicaltrials.gov) - Sep 29, 2016
P3, N=40, Completed, Sponsor: Novartis Korea Ltd.
Trial primary completion date: Nov 2016 --> Nov 2018 Enrolling by invitation --> Completed
- | PAN-90806 / PanOptica
Trial completion: Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD (clinicaltrials.gov) - Sep 28, 2016
P1, N=50, Completed, Sponsor: PanOptica, Inc.
Enrolling by invitation --> Completed Active, not recruiting --> Completed
- ||| Lucentis (ranibizumab) / Roche, Novartis
New P2 trial, New P3 trial: Intravitreal Ranibizumab (Lucentis (clinicaltrials.gov) - Sep 26, 2016
P2, N=28, Not yet recruiting, Sponsor: LEANDRO CABRAL ZACHARIAS
- || Vabysmo (faricimab-svoa) / Roche
Trial primary completion date: AVENUE: A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (clinicaltrials.gov) - Sep 7, 2016
P2, N=271, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Trial primary completion date: Apr 2017 --> Jul 2017
- Raptiva (efalizumab) / Roche, EMD Serono, Xoma, Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study (clinicaltrials.gov) - Aug 26, 2016
P1, N=0, Withdrawn, Sponsor: Johns Hopkins University
Trial primary completion date: Apr 2017 --> Jul 2017 N=72 --> 0
- ||||||| Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial completion, HEOR: Protocol T: Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema (clinicaltrials.gov) - Aug 26, 2016
P3, N=660, Completed, Sponsor: Jaeb Center for Health Research
N=72 --> 0 Active, not recruiting --> Completed
- |||| ASP8232 / Astellas
Trial completion: A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME) (clinicaltrials.gov) - Aug 25, 2016
P2, N=96, Completed, Sponsor: Astellas Pharma Europe B.V.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: aiRTo-PDR: 25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial (clinicaltrials.gov) - Aug 25, 2016
P3, N=200, Recruiting, Sponsor: JUNYAN ZHANG
Active, not recruiting --> Completed Trial primary completion date: Jul 2016 --> Dec 2016
- ||||| Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: 24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME. (clinicaltrials.gov) - Aug 25, 2016
P4, N=80, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: RaTAPDR: 25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China (clinicaltrials.gov) - Aug 24, 2016
P2/3, N=120, Recruiting, Sponsor: JUNYAN ZHANG
Trial primary completion date: Jul 2016 --> Dec 2016 Trial primary completion date: Mar 2016 --> Mar 2017
- |||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: CAPTAIN: Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Aug 23, 2016
P4, N=70, Recruiting, Sponsor: Johannes Gutenberg University Mainz
Trial primary completion date: Mar 2016 --> Mar 2017 Not yet recruiting --> Recruiting
- |||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Trial primary completion date: Ranibizumab and Bevacizumab for Diabetic Macular Edema (clinicaltrials.gov) - Aug 19, 2016
P2, N=56, Completed, Sponsor: National Eye Institute (NEI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Aug 2015 --> Feb 2015
- ||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: OLIMPIC: A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. (clinicaltrials.gov) - Aug 16, 2016
P3, N=200, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Aug 2015 --> Feb 2015 Active, not recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
New P4 trial, Monotherapy: Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose (clinicaltrials.gov) - Aug 12, 2016
P4, N=40, Not yet recruiting, Sponsor: Seoul National University Hospital
- Lucentis (ranibizumab) / Roche, Novartis, Fovista (pegpleranib) / Roche, Astellas
New P1/2 trial: A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab (clinicaltrials.gov) - Aug 9, 2016
P1/2, N=7, Not yet recruiting, Sponsor: National Eye Institute (NEI)
- || ASP8232 / Astellas
Trial primary completion date: A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME) (clinicaltrials.gov) - Aug 8, 2016
P2, N=96, Active, not recruiting, Sponsor: Astellas Pharma Europe B.V.
Active, not recruiting --> Completed Trial primary completion date: Apr 2016 --> Aug 2016
- Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy. (clinicaltrials.gov) - Aug 8, 2016
P2, N=40, Recruiting, Sponsor: Greater Houston Retina Research
Trial primary completion date: Apr 2016 --> Aug 2016 Trial primary completion date: Aug 2016 --> Dec 2016
- Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration (clinicaltrials.gov) - Aug 8, 2016
P1/2, N=100, Recruiting, Sponsor: Southern California Desert Retina Consultants, MC
Trial primary completion date: Aug 2016 --> Dec 2016 Trial primary completion date: Sep 2017 --> Dec 2018
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Safety and Efficacy of Ranibizumab for Diabetic Macular Edema (clinicaltrials.gov) - Aug 8, 2016
P1/2, N=30, Active, not recruiting, Sponsor: Justis Ehlers
Trial primary completion date: Sep 2017 --> Dec 2018 Trial primary completion date: Jun 2016 --> Jun 2017
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Aug 8, 2016
P1, N=0, Withdrawn, Sponsor: William Beaumont Hospitals
Trial primary completion date: Jun 2016 --> Jun 2017 N=10 --> 0
- Lucentis (ranibizumab) / Roche, Novartis
New trial: Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Aug 5, 2016
P=N/A, N=90, Recruiting, Sponsor: Sun Yat-sen University
- ||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Enrollment change, Trial primary completion date, Head-to-Head: DIVERSE: Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema (clinicaltrials.gov) - Aug 4, 2016
P4, N=135, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=10 --> 0 Recruiting --> Active, not recruiting | N=300 --> 135 | Trial primary completion date: Sep 2017 --> Jun 2017
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: TWEYES: Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye (clinicaltrials.gov) - Aug 4, 2016
P4, N=1045, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=300 --> 135 | Trial primary completion date: Sep 2017 --> Jun 2017 Active, not recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Head-to-Head: RELIANCE: Head to Head Study of Anti-VEGF Treatment. (clinicaltrials.gov) - Aug 2, 2016
P4, N=12, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Completed
- ||||| Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: CAPTAIN: Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Jul 25, 2016
P4, N=70, Not yet recruiting, Sponsor: Johannes Gutenberg University Mainz
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity (clinicaltrials.gov) - Jul 20, 2016
P3, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Trial primary completion date: Nov 2017 --> Apr 2018
- ||||||| Lucentis (ranibizumab) / Roche, Novartis
Clinical protocol, Trial completion: ECLIPSE: An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. (clinicaltrials.gov) - Jul 20, 2016
P3, N=272, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Nov 2017 --> Apr 2018 Active, not recruiting --> Completed
- ||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: SAFARI: Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD (clinicaltrials.gov) - Jul 19, 2016
P4, N=124, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=162 --> 124
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron
Phase classification: TITAN: Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD (clinicaltrials.gov) - Jul 19, 2016
P4, N=225, Recruiting, Sponsor: Bayer
N=162 --> 124 Phase classification: P=N/A --> P4
- ||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Combination therapy: Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE) (clinicaltrials.gov) - Jul 19, 2016
P4, N=107, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Phase classification: P=N/A --> P4 Recruiting --> Active, not recruiting
- || Ozurdex (dexamethasone intravitreal implant) / AbbVie, Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Phase II Combination Steroid and Anti-VEGF for Persistent DME (clinicaltrials.gov) - Jul 19, 2016
P2, N=125, Recruiting, Sponsor: Diabetic Retinopathy Clinical Research Network
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2016 --> Jul 2017
- LMG324 / Novartis, Lucentis (ranibizumab) / Roche, Novartis
Enrollment change, Trial termination, Trial primary completion date: Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Jul 19, 2016
P1/2, N=25, Terminated, Sponsor: Alcon Research
Trial primary completion date: Dec 2016 --> Jul 2017 N=106 --> 25 | Recruiting --> Terminated | Trial primary completion date: Jun 2017 --> May 2016; Management decision
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change, Trial termination, Trial primary completion date: Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab (clinicaltrials.gov) - Jul 18, 2016
P2/3, N=20, Terminated, Sponsor: Kang Zhang, MD, PhD
N=106 --> 25 | Recruiting --> Terminated | Trial primary completion date: Jun 2017 --> May 2016; Management decision N=40 --> 20 | Recruiting --> Terminated | Trial primary completion date: Aug 2012 --> Mar 2015; Per study sponsor decision.
- | Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy (clinicaltrials.gov) - Jul 15, 2016
P4, N=25, Not yet recruiting, Sponsor: Wonkwang University Hospital
- |||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: RainbowExt: Rainbow Extension Study (clinicaltrials.gov) - Jul 11, 2016
P3, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
N=40 --> 20 | Recruiting --> Terminated | Trial primary completion date: Aug 2012 --> Mar 2015; Per study sponsor decision. Not yet recruiting --> Recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 (clinicaltrials.gov) - Jul 7, 2016
P0, N=11, Completed, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Enrollment change, Trial primary completion date: The LIMO Study, Lucentis for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema (clinicaltrials.gov) - Jul 6, 2016
P2, N=10, Completed, Sponsor: Moorfields Eye Hospital NHS Foundation Trust
Active, not recruiting --> Completed Recruiting --> Completed | N=20 --> 10 | Trial primary completion date: Feb 2013 --> Jun 2014
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Enrollment change, Trial initiation date, Trial primary completion date: Efficacy and Safety of Lucentis (clinicaltrials.gov) - Jul 1, 2016
P4, N=21, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=20 --> 10 | Trial primary completion date: Feb 2013 --> Jun 2014 Not yet recruiting --> Active, not recruiting | N=60 --> 21 | Initiation date: Jun 2014 --> Apr 2015 | Trial primary completion date: Apr 2015 --> Jan 2017
- ||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) (clinicaltrials.gov) - Jul 1, 2016
P3, N=283, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Active, not recruiting | N=60 --> 21 | Initiation date: Jun 2014 --> Apr 2015 | Trial primary completion date: Apr 2015 --> Jan 2017 Active, not recruiting --> Completed
- ||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Camellia: Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) (clinicaltrials.gov) - Jul 1, 2016
P3, N=252, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| acrizanib (LHA510) / Novartis
Enrollment closed, Enrollment change: LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration (clinicaltrials.gov) - Jun 28, 2016
P2, N=135, Active, not recruiting, Sponsor: Alcon, a Novartis Company
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=70 --> 135
- || Lucentis (ranibizumab) / Roche, Novartis
Trial completion: A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis (clinicaltrials.gov) - Jun 22, 2016
P3, N=35, Completed, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting | N=70 --> 135 Recruiting --> Completed
- ||||||| Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial completion: ARI2: Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration (clinicaltrials.gov) - Jun 21, 2016
P3, N=90, Completed, Sponsor: Centre Hospitalier Intercommunal Creteil
Recruiting --> Completed Active, not recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
New P4 trial, Combination therapy, Monotherapy: RANTA: Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy (clinicaltrials.gov) - Jun 21, 2016
P4, N=120, Not yet recruiting, Sponsor: Aier School of Ophthalmology, Central South University
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Enrollment change, Trial primary completion date: Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments (clinicaltrials.gov) - Jun 11, 2016
P4, N=40, Completed, Sponsor: University Hospital, Bonn
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=20 --> 40 | Trial primary completion date: Sep 2013 --> Dec 2014
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Enrollment change, Trial primary completion date: Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients. (clinicaltrials.gov) - Jun 1, 2016
P=N/A, N=136, Completed, Sponsor: NJ Retina
Active, not recruiting --> Completed | N=20 --> 40 | Trial primary completion date: Sep 2013 --> Dec 2014 Recruiting --> Completed | N=300 --> 136 | Trial primary completion date: Sep 2016 --> Apr 2016
- ||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: LUMINOUS: Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (clinicaltrials.gov) - May 23, 2016
P=N/A, N=30490, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=300 --> 136 | Trial primary completion date: Sep 2016 --> Apr 2016 Recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Trial primary completion date: Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia (clinicaltrials.gov) - May 19, 2016
P1, N=10, Completed, Sponsor: University of New Mexico
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jul 2012 --> Jul 2014